Neurocrine Biosciences, Inc.
NBIX
$131.14
-$1.24-0.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 153.70M | 209.50M | 107.50M | 7.90M | 103.10M |
| Total Depreciation and Amortization | 7.50M | 7.70M | 7.30M | 7.60M | 7.10M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 108.00M | 195.50M | 26.30M | 73.00M | 38.00M |
| Change in Net Operating Assets | 119.20M | -185.20M | -39.10M | -23.70M | 94.30M |
| Cash from Operations | 388.40M | 227.50M | 102.00M | 64.80M | 242.50M |
| Capital Expenditure | 2.40M | -13.20M | -12.50M | -10.70M | -7.30M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -55.30M | -183.50M | -16.50M | 24.90M | -61.00M |
| Cash from Investing | -52.90M | -196.70M | -29.00M | 14.20M | -68.30M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 0.00 |
| Issuance of Common Stock | 37.30M | 45.60M | 14.40M | 32.10M | 10.00M |
| Repurchase of Common Stock | 0.00 | 0.00 | -17.70M | -150.00M | -300.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 37.30M | 45.60M | -3.30M | -117.90M | -290.00M |
| Foreign Exchange rate Adjustments | -- | -200.00K | 200.00K | -- | -300.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 372.80M | 76.20M | 69.90M | -38.90M | -116.10M |